Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 12/20 | 0.42 |
| ▸ | ACP1 | P24666 | 4/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786481 | 0.96 | HTR2A (0.41) | NPY1RACP1KCNA3 | |
| SCHEMBL7794815 | 0.96 | HTR2A (0.41) | NPY1RACP1KCNA3 | |
| SCHEMBL7786088 | 0.94 | NPY1R (0.40) | NPY1RACP1KCNA3 | |
| SCHEMBL7792449 | 0.94 | KCNA3 (0.41) | NPY1RKCNA3 | |
| SCHEMBL7792139 | 0.93 | ACP1 (0.41) | NPY1RACP1KCNA3 | |
| SCHEMBL7794705 | 0.92 | NPY1R (0.41) | NPY1RACP1KCNA3TLR7 | |
| SCHEMBL7794760 | 0.91 | ACP1 (0.42) | NPY1RACP1KCNA3 | |
| SCHEMBL7786391 | 0.90 | HTR2A (0.42) | NPY1RKCNA3 | |
| SCHEMBL7786238 | 0.90 | HTR2A (0.42) | NPY1RKCNA3 | |
| SCHEMBL7794782 | 0.89 | KCNA3 (0.41) | NPY1RKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906268-B1 | ALKYLOXYAMINO SUBSTITUTED FLUORENONES AND THEIR USE AS PROTEIN KINASE C INHIBITORS | AVENTIS PHARMA INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6004959-A | HYPOTENSIVE, ANTITUMOR, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS; ANGIOGENESIS AND ALVEOLAR MACROPHAGE ACTIVATION INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1999-12-21 | — | — | US | disclosed |